AliveCor v. Apple: Federal Circuit Affirms ECG Arrhythmia Patent Unpatentable
AliveCor, Inc. pursued a 751-day appeal at the Federal Circuit after Apple, Inc. successfully challenged the patentability of US9572499B2, covering methods and systems for arrhythmia tracking and scoring. On 7 March 2025, the Federal Circuit affirmed the unpatentability finding, delivering a decisive outcome for Apple and raising the stakes for ECG wearable patent enforcement.
Apple kills AliveCor’s arrhythmia patent at the Federal Circuit
AliveCor, Inc., holder of US9572499B2 directed to methods and systems for arrhythmia tracking and scoring, brought this appeal to the United States Court of Appeals for the Federal Circuit (Case No. 23-1513) after an adverse patentability ruling below. The patent, filed under application number US14/730122, sits at the core of AliveCor’s cardiac monitoring technology portfolio and has commercial relevance to ECG-enabled wearable devices — a category dominated by Apple Watch.
The Federal Circuit, on 7 March 2025, issued a straightforward affirmance: the panel found no reversible error in the prior unpatentability determination and ordered the result affirmed. The basis of termination is recorded as ‘Unpatentable’, confirming that the claims of US9572499B2 have been cancelled. For AliveCor, this extinguishes the enforceability of this patent against Apple and any third party. For Apple, the affirmance eliminates a live patent threat tied to its ECG wearable features.
A 751-day appellate duration suggests a substantive and contested proceeding, consistent with the high-profile commercial stakes between these two parties. The public record does not disclose whether any claims survived in amended form or whether parallel proceedings remain active. Given AliveCor’s broader patent portfolio and ongoing commercial tension with Apple in the cardiac monitoring space, this decision likely represents one chapter in a wider IP dispute rather than a final resolution of the competitive relationship.
Filing to Unpatentable in 751 days
751 days on appeal — above the Federal Circuit median for patentability disputes
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the lower unpatentability finding is final
When the Federal Circuit issues an AFFIRMED disposition in a patentability appeal, it confirms that the panel identified no reversible error in the decision below. The standard of review for factual findings is substantial evidence; legal conclusions are reviewed de novo. Here, the affirmance validates the prior determination that the claims of US9572499B2 are unpatentable, giving that ruling preclusive effect.
No reversible error foundAliveCor loses US9572499B2 — enforceability extinguished
With the affirmance, AliveCor’s US9572499B2 claims covering arrhythmia tracking and scoring methods are cancelled. The patent can no longer be asserted against Apple or any other party. AliveCor’s remaining enforcement options are narrow: petition for rehearing en banc or certiorari to the Supreme Court, both of which face high bars. The commercial impact is significant given the patent’s relevance to ECG wearable functionality.
Patent cancelled — unenforceableApple secures freedom to operate on challenged ECG patent claims
Apple’s successful defence of the patentability challenge through to Federal Circuit affirmance removes a material IP risk from its Apple Watch ECG product line. The affirmance raises the bar for any future challenge to this outcome. Apple deployed three law firms — Fish & Richardson, Orrick, and White & Case — signalling the strategic priority placed on this result, and that investment has now delivered a durable outcome.
Freedom to operate securedWearable ECG sector: patent landscape shifts in Apple’s favour
The cancellation of a core AliveCor arrhythmia-tracking patent strengthens Apple’s position in the consumer ECG wearable market. Competitors and licensees in the cardiac monitoring space should audit their own portfolio exposure. The ruling also signals that the Federal Circuit will apply rigorous patentability scrutiny to method claims in digital health — potentially affecting the enforceability of similar claim structures across the sector.
Wearable ECG patent risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AliveCor, Inc. | Company | Cardiac monitoring technology company — holder of US9572499B2 (arrhythmia tracking)Search in Eureka ↗ |
| Defendant | Apple, Inc. | Company | Apple, Inc. — consumer electronics and wearables manufacturer, maker of Apple Watch ECGSearch in Eureka ↗ |
| Plaintiff counsel | Sean S. Pak | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William Adams | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Quinn Emanuel Urquhart & Sullivan, LLP | Law Firm | Representing AliveCor, Inc.Search in Eureka ↗ |
| Defendant counsel | Benjamin Elacqua | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark S. Davies | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Melanie L. Bostwick | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael Ari Amon | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Ruffin B. Cordell | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Walter Karl Renner | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson PC | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Orrick, Herrington & Sutcliffe LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | White & Case LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a merits affirmance of the unpatentability finding below. The basis of termination as ‘Unpatentable’ confirms claim cancellation rather than a procedural or jurisdictional dismissal. Under Federal Circuit review, factual determinations are assessed for substantial evidence and legal conclusions de novo; the panel’s affirmance suggests AliveCor could not meet either standard to disturb the prior ruling.
US9572499B2 — Methods and Systems for Arrhythmia Tracking and Scoring
US9572499B2, filed under application number US14/730122, covers methods and systems for arrhythmia tracking and scoring — technology that sits at the intersection of ECG signal processing, cardiac event classification, and wearable device implementation. The patent’s claims describe a framework for detecting, recording, and scoring arrhythmic events from electrocardiographic data, a capability central to consumer-facing heart health monitoring. The application date context suggests development in the period before widespread wearable ECG adoption.
Strategically, this patent represented AliveCor’s attempt to assert foundational IP over arrhythmia-scoring methodology in a space now commercially dominated by Apple Watch’s ECG and AFib detection features. The Federal Circuit’s affirmance of unpatentability removes this specific asset from AliveCor’s enforcement arsenal, but the underlying technical domain — automated cardiac arrhythmia classification in wearables — remains heavily contested IP territory. Any company building ECG-based scoring algorithms into consumer hardware or software should monitor the surrounding patent landscape closely.
Should your team run an FTO analysis against US9572499B2?
Although US9572499B2 has been affirmed unpatentable and its claims cancelled, R&D and product teams working on arrhythmia detection, ECG signal scoring, or wearable cardiac monitoring should not treat this as a blanket clearance. AliveCor holds related patents and pending applications that may cover similar technical territory. The cancellation of one patent in a family does not extinguish risk from continuation or divisional claims with overlapping disclosure.
PatSnap Eureka’s FTO Search Agent allows product teams to map the full AliveCor patent family, identify live related applications sharing the US14/730122 priority chain, and assess claim language against specific product features — arrhythmia classification algorithms, ECG data processing pipelines, or scoring output displays. Run a targeted FTO before finalising any wearable cardiac monitoring product roadmap to confirm your specific implementation falls outside the scope of any surviving claims.
Run a freedom-to-operate analysis on US9572499B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patentability appeals in wearable ECG and digital health
Federal Circuit patentability appeals involving ECG, cardiac monitoring, and wearable health methods — comparable in scope and claim type to AliveCor v. Apple.
What this case signals for the digital health and wearable ECG IP landscape
The Federal Circuit’s affirmance has implications well beyond AliveCor and Apple — ECG wearable and cardiac monitoring patent holders should take note.
Method claims in digital health face heightened patentability scrutiny
The affirmance of unpatentability for arrhythmia tracking method claims at the Federal Circuit is consistent with a broader pattern of challenging software-implemented medical method patents. Portfolio owners in cardiac monitoring, remote patient monitoring, and AI-driven diagnostics should proactively audit claim structures for patentability vulnerability before enforcement.
Apple’s multi-firm defence strategy signals long-term ECG IP commitment
Retaining Fish & Richardson, Orrick, and White & Case simultaneously suggests Apple treated this appeal as a high-priority strategic matter, not a routine defence. Companies competing in the Apple Watch ECG space should anticipate well-resourced opposition to any patent assertions touching wearable cardiac monitoring features.
AliveCor v Apple — key questions answered
The Federal Circuit affirmed the unpatentability of US9572499B2 on 7 March 2025. The basis of termination is recorded as ‘Unpatentable’, meaning the patent claims covering methods and systems for arrhythmia tracking and scoring have been cancelled and are no longer enforceable against Apple or any third party.
US9572499B2 covers methods and systems for arrhythmia tracking and scoring using ECG data — technology directly relevant to the arrhythmia detection and AFib classification features in Apple Watch. AliveCor asserted this patent as part of its broader IP dispute with Apple over wearable cardiac monitoring functionality.
An affirmance from the Federal Circuit means the appellate panel found no reversible error in the decision below. Factual findings are reviewed for substantial evidence and legal conclusions de novo. In this case, the prior unpatentability determination survived both standards, confirming claim cancellation with preclusive effect.
Not necessarily. The public record for this case covers only US9572499B2. AliveCor holds a broader patent portfolio in cardiac monitoring, and related continuation or divisional applications may remain active. The cancellation of this specific patent does not confirm freedom to operate across AliveCor’s entire ECG and arrhythmia IP portfolio.
Apple engaged Fish & Richardson PC, Orrick Herrington & Sutcliffe LLP, and White & Case LLP simultaneously on this appeal. While the reasons are not disclosed in the public record, the multi-firm approach is consistent with high-stakes appellate matters where breadth of technical, appellate, and strategic IP expertise is commercially justified — particularly where the outcome could affect a major product line like Apple Watch.
PatSnap Eureka searches patents and litigation data to answer instantly.